Evaxion A/S (EVAX) stock
Close on Nov 11, 2026Market cap $24.27MP/E –Yield –
Evaxion A/S grew revenue 125.1% to $7.53M over fiscal 2025. Free cash flow was -$6.64M. At the latest close the market valued the company at $24.27M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $24.27M
- P/E ratio
- –
- Price to sales
- 3.22
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -27.34%
Fundamentals
- Revenue
- $7.53M
- Net income
- -$7.71M
- Free cash flow
- -$6.64M
Trading
- Previous close
- $2.86
- Open
- $2.96
- Day's range
- $2.85 – $2.96
- Volume
- 21,899
- Average volume (20 days)
- 137,365
- Beta (5 years)
- 1.24
- 52-week range
- $2.67 – $6.92
- RSI (14 days)
- 45.8
- Volatility (1 year)
- 80.2%
- Relative volume
- 0.12×
- WACC
- 11.2%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EVAX | S&P 500 | Difference | EVAX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.2% | -2.4% | −2.8 pts | ||
| 3 months | -4.9% | -1.2% | −3.8 pts | ||
| Year to date | -39.0% | +12.3% | −51.3 pts | ||
| 1 year | -51.5% | +12.4% | −63.9 pts | ||
| 3 years | -92.2% | +78.8% | −171.1 pts | -57.3% | +21.4% |
| 5 years | -99.1% | +75.2% | −174.2 pts | -60.7% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Evaxion A/S filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Evaxion A/S
Biological Products, (No Diagnostic Substances)
Evaxion is a biotechnology company that develops targeted immunotherapies and vaccines for cancers and infectious diseases using its proprietary artificial intelligence platform, AI-Immunology. The platform identifies novel disease targets and predicts immune responses to engineer therapeutic cancer vaccines and prophylactic bacterial and viral treatments. Its clinical and preclinical research programs address conditions such as melanoma, leukemia, gonorrhea, and cytomegalovirus. The company generates value through its internal pipeline assets and strategic research collaborations, serving pharmaceutical companies and healthcare partners through licensing and co-development partnerships.
Company profile, executives and historyEvaxion A/S stock: common questions
What is Evaxion A/S's stock price?
EVAX closed at $2.91 on Nov 11, 2026, up 1.75% on the day. Over the past 52 weeks it traded between $2.67 and $6.92.
What is Evaxion A/S's market cap?
Evaxion A/S was worth $24.27M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Evaxion A/S make?
Evaxion A/S reported revenue of $7.53M for fiscal 2025, up 125.1% from a year earlier.
Does Evaxion A/S pay a dividend?
No. Evaxion A/S has not paid a cash dividend over the last twelve months.
How has EVAX stock performed over the past year?
Including dividends, EVAX returned -51.5% over the past year, against +12.4% for the S&P 500.
Who are Evaxion A/S's competitors?
Companies most similar to Evaxion A/S by business, industry and size include ATRA, IPHA, MOLN, TCRX, ELOX.
See a number that looks wrong?